论文部分内容阅读
本文报道了56例原发性肺癌患者外周血sIL—2R水平及表达mIL—2R活化T淋巴细胞数,并作了动态观察。结果显示,原发性肺癌患者sIL—2R水平明显高于对照组,经治疗达缓解期的患者sIL—2R水平可以下降,达进展期(恶化期)的患者sIL—2R水平比治疗前增高,而且sIL—2R水平越高,预后越差。另外,肺癌患者未诱导或诱导后表达mIL—2R活化细胞数略低于对照组,尤其是治疗后达进展期的患者经PHA诱导后表达mIL—2R的活化细胞数明显低于治疗前,也低于对照组,上述结果说明外周血sIL—2R水平及表达mIL—2R活化T淋巴细胞数与肺癌患者的病情变化、预后有关系,可作为临床观察的指标。
In this paper, the levels of sIL-2R and mIL-2R activated T lymphocytes in peripheral blood of 56 patients with primary lung cancer were reported and observed dynamically. The results showed that the level of sIL-2R in patients with primary lung cancer was significantly higher than that in the control group. The level of sIL-2R in patients with remission after treatment could be decreased, and the level of sIL-2R in patients with advanced stage (exacerbation) was higher than before treatment. And the higher the level of sIL-2R, the worse the prognosis. In addition, the number of mIL-2R-activated cells that were not induced or induced in lung cancer patients was slightly lower than that in the control group. In particular, the number of activated mIL-2R-expressing cells after PHA induction was significantly lower than before treatment in patients with advanced lung cancer after treatment. Lower than the control group, the above results indicate that the level of sIL-2R in peripheral blood and the number of activated T lymphocytes expressing mIL-2R are related to the disease condition and prognosis of lung cancer patients, and can be used as clinical observation indicators.